PE20230251A1 - Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2 - Google Patents
Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2Info
- Publication number
- PE20230251A1 PE20230251A1 PE2022000820A PE2022000820A PE20230251A1 PE 20230251 A1 PE20230251 A1 PE 20230251A1 PE 2022000820 A PE2022000820 A PE 2022000820A PE 2022000820 A PE2022000820 A PE 2022000820A PE 20230251 A1 PE20230251 A1 PE 20230251A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- alk2
- combination therapy
- jak2
- halo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a una terapia de combinacion que comprende un inhibidor de ALK2 y un inhibidor de JAK2; en donde el inhibidor de JAK2 tiene formula I, o una sal farmaceuticamente aceptable del mismo; caracterizado porque R1, R2 y R3 se seleccionan independientemente del grupo que consiste en H, halo y alquilo C1-4; R4 es H, halo, ciano, nitro, entre otros; Z es cicloalquilo de 3 a 6 miembros; un compuesto seleccionado del mismo es 3-ciclopentil-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propanonitrilo; y en donde el inhibidor de ALK2 de formula II, o una sal farmaceuticamente aceptable del mismo; caracterizado porque R1 es cicloalquilo de 5 a 10 miembros con puente opcionalmente sustituido una, dos o tres veces por hidroxilo o alcoxi C1-C3; R2 se selecciona del grupo que consiste de alquilo C1-C3, alquenilo C2-C4, alquinilo de C2-C4, entre otros; un compuesto seleccionado del mismo es 2-amino-N-(4-hidroxibiciclo[2.2.2]octan-1-il)-5-(4-(3-(tetrahidro-2H-piran-4-il)-3-azabiciclo[3.1.0]hexan-1-il)fenil)nicotinamida. Tambien se refiere a composiciones farmaceuticas que comprenden dichos compuestos y su uso en el tratamiento del cancer, como la neoplasia mieloproliferativa o un sindrome mielodisplasico.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962939241P | 2019-11-22 | 2019-11-22 | |
US202062980562P | 2020-02-24 | 2020-02-24 | |
US202063035194P | 2020-06-05 | 2020-06-05 | |
US202063056768P | 2020-07-27 | 2020-07-27 | |
PCT/US2020/061497 WO2021102258A1 (en) | 2019-11-22 | 2020-11-20 | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230251A1 true PE20230251A1 (es) | 2023-02-07 |
Family
ID=73699492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000820A PE20230251A1 (es) | 2019-11-22 | 2020-11-20 | Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2 |
Country Status (16)
Country | Link |
---|---|
US (2) | US11738026B2 (es) |
EP (1) | EP4061367A1 (es) |
JP (1) | JP2023502742A (es) |
KR (1) | KR20220107213A (es) |
CN (1) | CN115038443A (es) |
AU (1) | AU2020388638A1 (es) |
BR (1) | BR112022009710A2 (es) |
CA (1) | CA3160312A1 (es) |
CL (1) | CL2022001325A1 (es) |
CR (1) | CR20220280A (es) |
EC (1) | ECSP22044525A (es) |
IL (1) | IL293085A (es) |
MX (1) | MX2022006176A (es) |
PE (1) | PE20230251A1 (es) |
TW (1) | TW202131926A (es) |
WO (1) | WO2021102258A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202214239A (zh) | 2020-06-16 | 2022-04-16 | 美商英塞特公司 | 用於治療貧血之alk2抑制劑 |
WO2023081212A1 (en) * | 2021-11-02 | 2023-05-11 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
CN116478145B (zh) * | 2022-04-13 | 2024-02-02 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3832460A (en) | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US5077290A (en) | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
US6638905B2 (en) | 1993-06-18 | 2003-10-28 | The Salk Institute For Biological Studies | Cloning and recombinant production of CFR receptor(s) |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
CA2343148C (en) | 1998-09-10 | 2005-11-15 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
CN1195755C (zh) * | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3-d]嘧啶化合物 |
IL150388A0 (en) | 1999-12-24 | 2002-12-01 | Aventis Pharma Ltd | Azaindoles |
DK1142566T3 (da) | 2000-04-07 | 2004-02-09 | Medidom Lab | Oftalmologiske formuleringer på basis af ciclosporin, hyaluronsyre og polysorbat |
MXPA03000068A (es) | 2000-06-26 | 2003-09-25 | Pfizer Prod Inc | Compuestos de pirrolo (2,3-d)pirimidina como agentes inmunosupresores. |
SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
ES2274986T3 (es) | 2001-08-01 | 2007-06-01 | MERCK & CO., INC. | Derivados de benzimidazo 4,5-f/isoquinolinona. |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
JP4901102B2 (ja) | 2002-05-03 | 2012-03-21 | エクセリクシス, インク. | プロテインキナーゼモジュレーターおよびその使用方法 |
US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
US20040067985A1 (en) | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
SE0203753D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
JP2006518381A (ja) | 2003-02-07 | 2006-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール |
US20040265909A1 (en) | 2003-04-11 | 2004-12-30 | Jeff Blaney | Compound libraries and methods for drug discovery |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
WO2005067546A2 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
CA2567935C (en) | 2004-05-27 | 2009-10-27 | Pfizer Limited | Aminopyridine derivatives as selective dopamine d3 agonists |
US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US8633205B2 (en) | 2005-02-03 | 2014-01-21 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases |
AU2006234627C1 (en) | 2005-04-08 | 2009-11-26 | Eisai R & D Management Co., Ltd. | Therapeutic agent for dyskinesia |
CN101228161B (zh) | 2005-05-20 | 2012-10-10 | 沃泰克斯药物股份有限公司 | 适用作蛋白激酶抑制剂的吡咯并吡啶类 |
WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
AR059037A1 (es) | 2006-01-17 | 2008-03-12 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
CA2658362A1 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
AU2007316417B2 (en) | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
EA020777B1 (ru) | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
TWI444382B (zh) | 2008-03-11 | 2014-07-11 | Incyte Corp | 作為jak抑制劑之氮雜環丁烷及環丁烷衍生物 |
CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
CN106967070A (zh) | 2009-05-22 | 2017-07-21 | 因塞特控股公司 | 作为jak抑制剂的化合物 |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
BR112012008267B1 (pt) | 2009-10-09 | 2022-10-04 | Incyte Holdings Corporation | Derivados hidroxila, ceto e glucuronida de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1- il)-3-ciclopentilpropanonitrila |
CA2790070C (en) | 2010-02-18 | 2018-03-06 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
WO2012073143A1 (en) | 2010-12-01 | 2012-06-07 | Pfizer Inc. | Kat ii inhibitors |
WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
US9993480B2 (en) | 2011-02-18 | 2018-06-12 | Novartis Pharma Ag | mTOR/JAK inhibitor combination therapy |
SI2714677T1 (sl) | 2011-05-23 | 2018-12-31 | Merck Patent Gmbh | Piridinski in pirazinski derivati |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
SG2014013767A (en) | 2011-09-09 | 2014-05-29 | Lantheus Medical Imaging Inc | Compositions, methods, and systems for the synthesis and use of imaging agents |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
JP6430383B2 (ja) | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーVanderbilt University | 選択的bmp阻害剤としての縮合複素環化合物 |
SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
JP2016510745A (ja) | 2013-03-04 | 2016-04-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | Bmp阻害剤およびその使用方法 |
DK2970205T3 (da) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf |
US20150065447A1 (en) | 2013-08-20 | 2015-03-05 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
AU2016209321B2 (en) | 2015-01-20 | 2019-05-09 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds, compositions and method of using thereof |
CN109641871B (zh) * | 2016-07-20 | 2021-10-22 | 诺华股份有限公司 | 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途 |
WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
EP3840752A4 (en) | 2018-08-21 | 2022-05-18 | Sierra Oncology, Inc. | PLATELET COUNT AGNOSTIC METHODS FOR TREATMENT OF MYELOFIBROSIS |
EP4041243A4 (en) | 2019-09-27 | 2023-10-18 | Disc Medicine, Inc. | METHOD FOR TREATING ANEMIA IN CHRONIC DISEASES |
KR20220088699A (ko) | 2019-09-27 | 2022-06-28 | 디스크 메디슨, 인크. | 골수섬유증 및 관련 상태의 치료 방법 |
TW202214239A (zh) | 2020-06-16 | 2022-04-16 | 美商英塞特公司 | 用於治療貧血之alk2抑制劑 |
-
2020
- 2020-11-20 IL IL293085A patent/IL293085A/en unknown
- 2020-11-20 MX MX2022006176A patent/MX2022006176A/es unknown
- 2020-11-20 TW TW109140802A patent/TW202131926A/zh unknown
- 2020-11-20 EP EP20820023.8A patent/EP4061367A1/en active Pending
- 2020-11-20 JP JP2022529824A patent/JP2023502742A/ja active Pending
- 2020-11-20 WO PCT/US2020/061497 patent/WO2021102258A1/en unknown
- 2020-11-20 CN CN202080094112.1A patent/CN115038443A/zh active Pending
- 2020-11-20 KR KR1020227020597A patent/KR20220107213A/ko unknown
- 2020-11-20 CA CA3160312A patent/CA3160312A1/en active Pending
- 2020-11-20 BR BR112022009710A patent/BR112022009710A2/pt unknown
- 2020-11-20 AU AU2020388638A patent/AU2020388638A1/en active Pending
- 2020-11-20 CR CR20220280A patent/CR20220280A/es unknown
- 2020-11-20 US US16/953,989 patent/US11738026B2/en active Active
- 2020-11-20 PE PE2022000820A patent/PE20230251A1/es unknown
-
2022
- 2022-05-19 CL CL2022001325A patent/CL2022001325A1/es unknown
- 2022-06-03 EC ECSENADI202244525A patent/ECSP22044525A/es unknown
-
2023
- 2023-07-12 US US18/351,278 patent/US20240041887A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023502742A (ja) | 2023-01-25 |
CR20220280A (es) | 2022-09-02 |
CA3160312A1 (en) | 2021-05-27 |
IL293085A (en) | 2022-07-01 |
US20210154195A1 (en) | 2021-05-27 |
TW202131926A (zh) | 2021-09-01 |
BR112022009710A2 (pt) | 2022-08-09 |
WO2021102258A1 (en) | 2021-05-27 |
CN115038443A (zh) | 2022-09-09 |
ECSP22044525A (es) | 2022-08-31 |
EP4061367A1 (en) | 2022-09-28 |
AU2020388638A1 (en) | 2022-06-30 |
CL2022001325A1 (es) | 2023-03-24 |
KR20220107213A (ko) | 2022-08-02 |
US11738026B2 (en) | 2023-08-29 |
US20240041887A1 (en) | 2024-02-08 |
MX2022006176A (es) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230251A1 (es) | Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
RU2441869C2 (ru) | Противовирусные соединения | |
ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
BRPI0612888B8 (pt) | anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica | |
AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
CR20160548A (es) | Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1 | |
AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
ATE456565T1 (de) | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren | |
ECSP066312A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
AR112392A1 (es) | Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende | |
AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
BRPI0408068A (pt) | derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
PE20110828A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak | |
EA200700099A1 (ru) | Производные пиридина | |
EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
CL2004000965A1 (es) | Compuestos derivados de 2h-pirazol-3-il de formula definida, que actuan como inhibidores de quinasa p38 y tnf; composicion farmaceutica que comprende a uno de los compuestos; uso de la composicion en la preparacion de un medicamento; y uso de los com | |
TW200626605A (en) | Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors |